TP53 and neoplasm: The analysis of tumor-derived organoids showed that KRASG12D is critical for liver metastatic capacity following splenic transplantation when this mutation was combined with APC deletion plus TP53 mutation or TGFBR2 deletion and showed the highest metastatic capacity when APC deletion was combined with KRASG12D and TGFBR2 deletion [298].